Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 10/20 | 0.67 |
| ▸ | HTR2C | P28335 | 4/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373743 | 1.00 | TAAR1 (1.00) | TAAR1HTR2AHTR2CHTR2BADRA1A | |
| Hydrochloric Acid SCHEMBL30559532 | 0.98 | TAAR1 (0.96) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL21240834 | 0.91 | TAAR1 (0.83) | TAAR1HTR2AHTR2CHTR2BADRA1A | |
| SCHEMBL29376427 | 0.88 | TAAR1 (0.78) | TAAR1HTR2AHTR2CHTR2BADRA1A | |
| SCHEMBL2562751 | 0.88 | TAAR1 (0.78) | TAAR1HTR2AHTR2CHTR2BADRA1A | |
| SCHEMBL1253319 | 0.87 | TAAR1 (0.77) | TAAR1HTR2AHTR2CADRA1A | |
| SCHEMBL29364056 | 0.87 | TAAR1 (0.77) | TAAR1HTR2AHTR2CADRA1A | |
| SCHEMBL2761495 | 0.86 | TAAR1 (0.76) | TAAR1HTR2AHTR2C | |
| SCHEMBL24163276 | 0.84 | TAAR1 (0.72) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL24163266 | 0.84 | TAAR1 (0.72) | TAAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | LDN Pharma Limited (GB) | 2024-09-05 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023114529-A2 | PHARMACOACTIVE FORMULATIONS FOR DELIVERY OF PSYCHEDELIC COMPOUNDS | BENNES, INC. (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | claimed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | claimed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | claimed |
| US-10775394-B2 | Immunoassay for phenethylamines of the 2C and DO sub-families | RANDOX LABORATORIES LIMITED (GB) | 2020-09-15 | — | — | US | claimed |
| EP-2835648-B1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | RANDOX LABORATORIES LTD (GB) | 2018-12-12 | — | — | EP | claimed |
| EP-2950104-B1 | IMMUNOASSAY FOR COMPOUNDS OF THE NBOME FAMILY | RANDOX LABORATORIES LTD (GB) | 2018-08-08 | — | — | EP | claimed |
| US-20180209998-A1 | IMMUNOASSAY FOR PHENETHYLAMINES OF THE 2C AND DO SUB-FAMILIES | RANDOX LABORATORIES LIMITED | 2018-07-26 | — | — | US | claimed |
| US-9720005-B2 | Immunoassay for compounds of the NBOMe family | RANDOX LABORATORIES LIMITED (GB) | 2017-08-01 | — | — | US | claimed |
| US-9435816-B2 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods of their preparation and their use | CHIRON AS (NO) | 2016-09-06 | — | — | US | claimed |
| US-20150216799-A1 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC | 2015-08-06 | — | — | US | claimed |
| EP-2884962-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | Smartek International LLC (US) | 2015-06-24 | — | — | EP | claimed |
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON A/S (NO) | 2014-08-14 | — | — | US | claimed |
| WO-2014028796-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC (US) | 2014-02-20 | — | — | WO | claimed |
| WO-2013014287-A2 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON AS (NO) | 2013-01-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10775394-B2 | Immunoassay for phenethylamines of the 2C and DO sub-families | PNMT, DDT, COMT | TAAR1 514/4885HTR2A 71/4885HTR2C 8/4885 |
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | PNMT, HTR2C, HTR2A | TAAR1 16/4885HTR2A 3/4885HTR2C 2/4885 |
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | HTR2C, HTR2B, HTR2A | TAAR1 47/4885HTR2A 3/4885HTR2C 1/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | TAAR1 128/4885HTR2A 11/4885HTR2C 6/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | TAAR1 26/4885HTR2A 2/4885HTR2C 5/4885 |
| US-20180209998-A1 | IMMUNOASSAY FOR PHENETHYLAMINES OF THE 2C AND DO SUB-FAMILIES | PNMT, DDT, COMT | TAAR1 514/4885HTR2A 71/4885HTR2C 8/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | TAAR1 128/4885HTR2A 11/4885HTR2C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.